NCT06906003

Brief Summary

Purpose: The aim of this study is to evaluate the impact of visual rehabilitation in visually impaired patients with advanced AMD by the use of questionnaires on the anxiety and depression status. Study design: prospective observational study. The study is carried out at the IRCCS Fondazione G.B.Bietti and at the UO Visual Rehabilitation, S. Alessio - Margherita di Savoia. Study procedures: Visit 1 (screening visit, at IRCCS Fondazione Bietti) After signing the informed consent, all patients received a complete ophthalmological examination, non-invasive diagnostic tests as optical coherence tomography, autofluorescence and microperimetry, and have to complete the questionnaires on the state of anxiety and depression (GAD-7 and PHQ-9). Visit 2 (at the Sant'Alessio Institute) for a 60-day visual rehabilitation program scheduled in 5 group meetings. Visit 3 (end-of-study visit, at IRCCS Fondazione G.B. Bietti) complete ophthalmological examination, as per clinical practice, non-invasive diagnostic tests such as microperimetry, optical coherence tomography and autofluorescence and administration of the Patient Health Questionnaire-9 (PHQ-9) questionnaires for depression and the General Anxiety Disorder (GAD-7) questionnaires for anxiety.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 2, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

February 27, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 2, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 2, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 2, 2025

Completed
Last Updated

April 2, 2025

Status Verified

February 1, 2025

Enrollment Period

1 year

First QC Date

February 27, 2025

Last Update Submit

March 25, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Changes of anxiety and depression status in visually impaired patients with AMD undergoing visual rehabilitation program

    Generalised Anxiety Disorder score (GAD-7, range 0-21,higher scores mean worse outcome) changes after rehabilitation program

    12 weeks

  • Changes of anxiety and depression status in visually impaired patients with AMD undergoing visual rehabilitation program

    Patient Health Questionnaire score (PHQ-9, range 0-27, higher scores mean worse outcome) changes after rehabilitation program

    12 weeks

Interventions

I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of "table" activities V. meeting: meeting with caregivers.

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Moderate and severe visually impaired patients affected by non exudative AMD

You may qualify if:

  • Subjects ≥ 55 years
  • Moderate and severe visual impairment (BCVA ≥1/10 and ≤2/10)
  • Diagnosis of advanced non-exudative age-related macular degeneration (AMD)
  • Informed consent freely granted and acquired before the start of the study
  • Ability to understand and willingness to follow the study instructions and procedures

You may not qualify if:

  • Visual impairment due to other ocular diseases
  • Mild visual impairment or partial or total blindness
  • Exudative age-related macular degeneration undergoing intravitreal drug treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Fondazione G.B.Bietti

Rome, Italy, 00184, Italy

RECRUITING

MeSH Terms

Conditions

Macular DegenerationAnxiety Disorders

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesMental Disorders

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2025

First Posted

April 2, 2025

Study Start

December 2, 2024

Primary Completion

December 2, 2025

Study Completion

December 2, 2025

Last Updated

April 2, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations